The Redwood City, Calif.-based company said it is looking to float approximately 2.2 million shares of its common stock at $1.64 per share, hoping to bring in approximately $3.6 million.
The offering will also include warrants for the purchase of half a share of common stock for each share purchased, with an exercise price of $1.58 per share. Warrants offered in the round will be exercisable for up to six months after the offering closes, and will expire three years from the date they were issued.
Ladenburg Thalmann & Co are acting as the exclusive placement agent for the offering, which the company expects to close on July 16, according to a press release.
Last month, Avinger said it launched its next-generation Pantheris in the US, touting that the first procedures with the device have already been performed.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.